The antibody drug conjugates market is projected to grow at an annualized rate of over 20%, till 2030


Presently, over 240 ADC therapy candidates are being evaluated in clinical / preclinical stages for treating a variety of solid tumors / hematologic cancers

.

With six marketed drugs, ADCs are presently recognized as a potent class of targeted anticancer therapies, with the potential to be used to treat a variety of other disease indications. The success of such products can be attributed to their ability to effectively identify and eliminate disease associated cells / pathogens, with substantially lower risk of treatment related side effects. Over the years, various technological advancements, such as antibody engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for antibody drug conjugates (ADCs) to be recognized as potent therapies targeting a wide range of indications, including solid tumors and hematological malignancies.

 

 

To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html

 

The USD 15 billion (by 2030) financial opportunity within this market has been analyzed across the following segments:

  • Type of Payload
  • MMAE
  • DM4
  • Camptothecin
  • DM1
  • MMAF
  • Others

 

  • Type of Linker
  • VC
  • Sulfo-SPDB
  • SMCC
  • VA
  • Hydrazone
  • Others

 

  • Target Indication
  • Breast cancer
  • Lymphoma
  • Leukemia
  • Urothelial cancer
  • Lung cancer
  • Ovarian cancer
  • Others

 

  • Target Antigen
  • CD30
  • HER2
  • CD22
  • CD33
  • Others

 

  • Technology Providers
  • Seattle Genetics
  • ImmunoGen
  • StemCentRx
  • Immunomedics
  • Others

 

  • Key Geographical Regions
  • North America
  • Europe
  • Asia Pacific

 

The Antibody Drug Conjugates Market (5th Edition), 2019-2030.” report features the following companies, which we identified to be key players in this domain:

  • Bristol Myers Squibb
  • GlaxoSmithKline
  • Incyte
  • Novartis
  • Trillium Therapeutics

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction
  3. Market Overview
  4. Company and Drug Profiles
  5. Key Therapeutic Areas
  6. Key Opinion Leaders
  7. Target Competitiveness Analysis
  8. Partnerships and Collaborations
  9. Funding and Investment Analysis
  10. Patent Analysis
  11. Academic Grants
  12. Key Commercialization Strategies

 

  1. Promotional Analysis

 

  1. Combination Therapies

 

  1. Novel Conjugation Technology Platforms

 

  1. Assessment of Non-Clinical Data, First in Human Dosing

 

  1. Cost Price Analysis

 

  1. Case Study: Contract Manufacturing of ADC

 

  1. Case Study: Companion Diagnostics for ADC Therapeutic

 

  1. Market Forecast and Opportunity Analysis

 

  1. Swot Analysis
  2. Conclusion

 

  1. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Medium - https://medium.com/@RootsAnalysis

Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/

Quora - https://rootsanalysisinsights.quora.com/

Comentários